New Order Addressing State Court Coordination Ruled by Federal Court Overseeing Testosterone Lawsuits

Heart attack striking a young man.jpgOn January 7th, a new order was issued by the federal court. This order was directly related to the state court litigations revolving around testosterone lawsuit proceedings that involve similar claims currently underway in multiple state courts. The order appointed a number of plaintiffs’ attorneys to act as representatives with state proceedings in Illinois, Missouri, Pennsylvania, California and Indiana and also for other state cases classified in the future. This should help speed up settlements for the men injured by these drugs.

An estimated 620 low testosterone therapy lawsuits have been filed in the Northern District of Illinois in defense of men who claim to have suffered strokes, heart attacks, life-threatening cardiovascular events, deep vein thrombosis and pulmonary embolism as a result of their low testosterone treatment. At the forefront of the cases, the plaintiffs allege that the manufacturers of the prescribed drugs concealed their potentially severe side effects from public knowledge and did not warn doctors and patients about the risks. The injured men also propose that sales of the medications were driven by misleading marketing claims that promoted the drugs to be effective remedies for male aging symptoms, and that those claims have now injured many once healthy men that used the drugs without true medical need.

Court documents reveal that the “Low T” litigation has been growing since January of last year when the FDA published a safety announcement stating they were investigating the medications in question. Since that time, FDA advisors have encouraged the labels be updated to reflect that the drugs have not been proved to lessen muscle loss, fatigue, low libido and other male aging symptoms. The FDA advisors has also required manufacturers to conduct cardiovascular side effect studies on their drugs.

More suits are being filed as this case grows even more in 2015.

Leave a Reply

Your email address will not be published. Required fields are marked *